Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, discusses the importance of raising awareness about genomic testing in patients with chronic lymphocytic leukemia (CLL) prior to treatment initiation. Prof. Ghia further describes the emergence of novel biomarkers in CLL which are currently under investigation. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.